@article{3220806,
    title = "Lichenoid drug eruption associated with imatinib mesylate therapy",
    author = "Alexandris, D. and Alevizopoulos, N. and Marinos, L. and Kanellis, G. and Gakiopoulou, C.",
    journal = "Journal of Oncology Pharmacy Practice",
    year = "2022",
    publisher = "SAGE Publications Ltd",
    issn = "1078-1552, 1477-092X",
    doi = "10.1177/10781552221096846",
    abstract = "Introduction: Imatinib Mesylate (IM), a tyrosine kinase inhibitor, has been reported to cause several adverse reactions, most of them with cutaneous involvement. Non- Lichenoid IM associated skin reactions have been sufficiently- recorded. To our knowledge, Lichenoid Drug Eruption (LDE) is recorded in a minority of registries. Case report: To describe an LDE induced case by IM treatment. Treatment and outcome: Histological Confirmation and promptly dermatological consultation relieved successfully the cutaneous adverse event. Discussion: Ongoing expansion of IM usage in a wide spectrum of new indications is more likely to make physicians experience such LDE cutaneous side effects more often. Hence, they should be highly suspicious to early detect these distinct histologic entities, handle these undesired complications and guarantee satisfactory immediate outcomes, avoiding frivolous IM dosage modifications. © The Author(s) 2022."
}